Kedrion President and CEO Paolo Marcucci discusses Kedrion's goal to strengthen its role as strategic partner of national health systems.
In this issue, we explore novel technologies shaping the future of the healthcare landscape.
David T. Rubin MD, assistant professor of medicine at the University of Chicago Pritzker School of Medicine, is a leading authority on Crohn’s disease and ulcerative colitis.
Tom Robinson refused to passively accept his diagnosis of debilitating Crohn’s disease and instead embarked on a journey that not only restored his health but launched a new career.
Results from a routine physical permanently altered the course of Jacques Whitfield’s life by revealing he was HIV positive. But for this patient-turned-advocate, promoting prevention has become his life’s passion.
As we celebrate our third year in publication, we begin by exploring innovations in vaccine research and technology.
Brent MacGregor, president of Novartis Vaccines, U.S., plans to build upon the current Novartis Vaccines culture, which he says promotes an entrepreneurial spirit coupled with an element of risk-taking that he thrives on.
Improved medications and lowered mortality rates have tasked providers with helping patients not only adhere to treatment plans, but also navigate the emotional and social implications of living long term with HIV.
With a global presence in more than90 countries, Grifols had long established itself as a standard-bearer within the plasma therapies industry.
With the number of counterfeit drug investigations having grown almost tenfold in the last five years, the number of prescription drug shortages nearly tripling from 2005 to 2010, and with recent indications that this threat is increasing rather than diminishing, keeping patients safe has never been more challenging.
High school athlete Jessica Hayes was healthy, active and had no family history of blood disorders. Her sudden-onset diagnosis of acquired hemophilia demonstrates the unpredictable nature of this rare and often life-threatening disease.
In the world of immune globulin, the demonstrated potential of these miraculous proteins to save and sustain lives is often thwarted by the complex and intertwined encumbrances that continually create barriers to access.